Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Post by Pronorvistaon Apr 18, 2023 2:12pm
156 Views
Post# 35401154

Ate

AteEn tant qu'entrepreneur et investisseur en srie, Yung a cr des entreprises rvolutionnaires grande chelle dans les domaines des logiciels d'entreprise, de l'analyse mobile et du big data, des mdias et du divertissement, des services technologiques et de la biotechnologie. Il est co-fondateur de deux organisations but non lucratif, la Coalition of Innovation Leaders Against Racism (CILAR) et DifferentIsCool (DiSC). Il sige actuellement aux conseils d'administration d'OMERS, de la Chambre de commerce de la rgion de Toronto, d'Antibe Therapeutics Inc. (TSX : ATE) et est membre de Green Shield Canada. Il est nomm par le gouverneur en conseil au Conseil consultatif canadien sur la consommation nette zro. Il a t reconnu comme l'un des « Top 40 under 40 » du Canada et pour avoir dirig l'une des « 50 socits prives les mieux gres » au pays. Wu a un B.Sc. Informatique, conomie et mathmatiques de l'Universit de Toronto et diplm du programme de matrise en entrepreneuriat du Massachusetts Institute of Technology, du programme de certification de surveillance de la cyberscurit NACD de l'Universit Carnegie Mellon, membre de MENSA, l'organisation des jeunes prsidents (YPO) et l'Institut des administrateurs de socits (IAS.D).
<< Previous
Bullboard Posts
Next >>